keyword
MENU ▼
Read by QxMD icon Read
search

Medroxyprogesterone acetate

keyword
https://www.readbyqxmd.com/read/29351618/maintenance-hormonal-therapy-after-treatment-with-medroxyprogesterone-acetate-for-patients-with-atypical-polypoid-adenomyoma
#1
Hidetaka Nomura, Yuko Sugiyama, Terumi Tanigawa, Maki Matoda, Sanshiro Okamoto, Kohei Omatsu, Hiroyuki Kanao, Kazuyoshi Kato, Kuniko Utsugi, Nobuhiro Takeshima
Background: As atypical polypoid adenomyoma (APA) has been reported to be a hormone-related tumor, we aimed to analyze the efficacy and safety of maintenance hormonal therapy after fertility-preserving treatment of these patients with medroxyprogesterone acetate (MPA). Methods: Data were retrospectively analyzed from patients with APA who were treated with a fertility-preserving regimen including MPA between October 2001 and December 2011. Eighteen patients were treated with MPA and 14 (77...
January 17, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29334191/exogenous-oestrogen-inhibits-genital-transmission-of-cell-associated-hiv-1-in-dmpa-treated-humanized-mice
#2
Nirk E Quispe Calla, Rodolfo D Vicetti Miguel, Melissa E Glick, Jesse J Kwiek, Janelle M Gabriel, Thomas L Cherpes
INTRODUCTION: HIV affects more women than any other life-threatening infectious agent, and most infections are sexually transmitted. HIV must breach the female genital tract mucosal barrier to establish systemic infection, and clinical studies indicate virus more easily evades this barrier in women using depot-medroxyprogesterone acetate (DMPA) and other injectable progestins for contraception. Identifying a potential mechanism for this association, we learned DMPA promotes susceptibility of wild-type mice to genital herpes simplex virus type 2 (HSV-2) infection by reducing genital tissue expression of the cell-cell adhesion molecule desmoglein-1 (DSG-1) and increasing genital mucosal permeability...
January 2018: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/29325482/reply-to-letter-to-editor-regarding-correlation-between-uterine-artery-doppler-indices-and-menstrual-irregularities-among-levonorgestrel-releasing-intrauterine-system-and-depot-medroxyprogesterone-acetate-users-a-prospective-observational-study
#3
Mohamed Rezk, Alaa Al-Halaby, Mohamed Emarh, Mohamed Shawky
No abstract text is available yet for this article.
January 12, 2018: European Journal of Contraception & Reproductive Health Care
https://www.readbyqxmd.com/read/29309550/hormonal-contraception-and-hiv-1-acquisition-biological-mechanisms
#4
Janet P Hapgood, Charu Kaushic, Zdenek Hel
Access to effective affordable contraception for women is critical for individual and public health. A wide range of hormonal contraceptives (HCs) which differ in the composition, concentration of progestin component, frequency of dosage and method of administration, is currently available globally. However, the options are rather limited in settings with restricted economic resources that frequently overlap with areas of high HIV-1 prevalence. The predominant contraceptive used in Sub-Saharan Africa is the progestin-only three-monthly injectable depo-medroxyprogesterone acetate (DMPA)...
January 4, 2018: Endocrine Reviews
https://www.readbyqxmd.com/read/29300975/new-application-of-dydrogesterone-as-a-part-of-a-progestin-primed-ovarian-stimulation-protocol-for-ivf-a-randomized-controlled-trial-including-516-first-ivf-icsi-cycles
#5
Sha Yu, Hui Long, Hannah Ya-Ning Chang, Yali Liu, Hongyuan Gao, Jing Zhu, Xinxin Quan, Qifeng Lyu, Yanping Kuang, Ai Ai
STUDY QUESTION: Can dydrogesterone (DYG) be used as an alternative progestin in a progesterone primed ovarian stimulation (PPOS) protocol? SUMMARY ANSWER: DYG can be used as an appropriate alternative progestin in a PPOS protocol. WHAT IS KNOWN ALREADY: PPOS is a new ovarian stimulation regimen based on a freeze-all strategy that uses progestin as an alternative to a GnRH analog for suppressing a premature LH surge during the follicular phase...
December 29, 2017: Human Reproduction
https://www.readbyqxmd.com/read/29278560/are-hormonal-contraceptives-less-effective-in-overweight-and-obese-women
#6
Shriya Patel, Lawrence Carey
Loss of efficacy of hormonal contraceptives is of particular concern for women who are overweight or obese. Only recently have clinical trials started to include overweight and obese women in their study populations, limiting the data available on which to make the best prescribing decisions for hormonal contraceptives for these patients. Other methods, such as the copper or levonorgestrel-containing intrauterine device, the etonogestrel implant, and depot medroxyprogesterone acetate, are preferred over combined oral contraceptives, the transdermal patch, and the vaginal ring...
January 2018: JAAPA: Official Journal of the American Academy of Physician Assistants
https://www.readbyqxmd.com/read/29259466/overexpression-of-microrna-542-3p-attenuates-the-differentiating-capacity-of-endometriotic-stromal-cells
#7
Shamima Sultana, Takeshi Kajihara, Yumi Mizuno, Tomomi Sato, Tatsuo Oguro, Machiko Kimura, Masumi Akita, Osamu Ishihara
Aim: Endometriosis is defined as the presence of endometrial glandular and stromal cells outside of the uterine cavity. A previous study reported that microRNA (miR)-542-3p plays a critical role in eutopic endometrial decidualization. This study aims to clarify the potential role of miR-542-3p and the target gene, IGFBP-1 (insulin-like growth factor-binding protein 1), in the impairment of the decidualizing capacity of human ectopic endometrial stromal cells (HEcESCs). Methods: In vitro analysis of primary undifferentiated and decidualizing human eutopic endometrial stromal cells (HEuESCs) and HEcESCs was conducted...
April 2017: Reproductive Medicine and Biology
https://www.readbyqxmd.com/read/29259453/polycystic-ovary-syndrome-early-diagnosis-and-intervention-are-necessary-for-fertility-preservation-in-young-women-with-endometrial-cancer-under-35%C3%A2-years-of-age
#8
Yoshinori Okamura, Fumitaka Saito, Kiyomi Takaishi, Takeshi Motohara, Ritsuo Honda, Takashi Ohba, Hidetaka Katabuchi
Aim: Polycystic ovary syndrome (PCOS) is a significant risk factor for premenopausal endometrial cancer (EC) and/or atypical endometrial hyperplasia (AEH). The aim was to elucidate the clinical background and detailed menstrual history of EC and/or AEH in young women with PCOS. Methods: From January 2001 to December 2013, women under 35 years of age who had been diagnosed with EC and/or AEH and who had been treated at Kumamoto University Hospital, Japan, were recruited...
January 2017: Reproductive Medicine and Biology
https://www.readbyqxmd.com/read/29247457/progestin-primed-ovarian-stimulation-with-or-without-clomiphene-citrate-supplementation-in-normal-ovulatory-women-undergoing-in-vitro-fertilization-intracytoplasmic-sperm-injection-a-prospective-randomized-controlled-trial
#9
Yali Liu, Qiuju Chen, Sha Yu, Yun Wang, Wen He, Hannah Ya-Ning Chang, Bian Wang, Hongyuan Gao, Hui Long, Li Wang, Qifeng Lyu, Ai Ai, Yanping Kuang
OBJECTIVE: To compare the endocrinological profiles, cycle characteristics and pregnancy outcomes of progestin-primed ovarian stimulation (PPOS) with or without clomiphene citrate (CC) supplementation in normal ovulatory women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). DESIGN: Prospective randomized controlled study. PATIENT(S): A total of 320 infertile women undergoing IVF/ICSI. Medroxyprogesterone acetate (MPA) and human menopausal gonadotropin (hMG) were simultaneously administered on menstrual cycle day 3...
December 16, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/29246819/discordance-between-self-reported-contraceptive-use-and-detection-of-exogenous-hormones-among-malawian-women-enrolling-in-a-randomized-clinical-trial
#10
Anuli N Nwaohiri, Jennifer H Tang, Frank Stanczyk, Lameck Chinula, Stacey Hurst, Nicole L Davis, Gerald Tegha, Lisa Haddad, Athena P Kourtis
OBJECTIVE: To assess the extent of concordance between self-reported contraceptive use and the presence of contraceptive progestins in serum. STUDY DESIGN: We evaluated self-reported contraceptive use by using radioimmunoassay to examine baseline serum levels of medroxyprogesterone acetate (MPA) and levonorgestrel (LNG) among 97 Malawian women enrolling in a contraceptive trial. RESULTS: Twelve percent (12/97) of study participants who reported no hormonal contraceptive use in the previous 6months had either MPA or LNG detected in their serum...
December 13, 2017: Contraception
https://www.readbyqxmd.com/read/29246818/increased-one-year-continuation-of-dmpa-among-women-randomized-to-self-administration-results-from-a-randomized-controlled-trial-at-planned-parenthood
#11
Julia E Kohn, Hannah R Simons, Lisa Della Badia, Elissa Draper, Johanna Morfesis, Elizabeth Talmont, Anitra Beasley, Melanie McDonald, Carolyn L Westhoff
OBJECTIVES: Self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-sc) is feasible, acceptable, and effective. Our objective was to compare one-year continuation of DMPA-sc between women randomized to self-administration versus clinic administration. STUDY DESIGN: We randomized 401 females ages 15-44 requesting DMPA at clinics in Texas and New Jersey to self-administration or clinic administration in a 1:1 allocation. Clinic staff taught participants randomized to self-administration to self-inject and observed the first injection; participants received instructions, a sharps container, and three doses for home use...
December 7, 2017: Contraception
https://www.readbyqxmd.com/read/29242082/is-a-lower-dose-subcutaneous-contraceptive-injectable-containing-depot-medroxyprogesterone-acetate-likely-to-impact-women-s-risk-of-hiv
#12
Chelsea B Polis, Sharon L Achilles, Zdenek Hel, Janet P Hapgood
No abstract text is available yet for this article.
December 11, 2017: Contraception
https://www.readbyqxmd.com/read/29225247/hypercalcemia-after-the-discontinuation-of-medroxyprogesterone-acetate
#13
Erina Yuasa-Shibasaki, Sumiyasu Ishii, Shunichi Matsumoto, Takuya Tomaru, Kazuhiko Horiguchi, Aya Osaki, Atsushi Ozawa, Nobuyuki Shibusawa, Tetsurou Satoh, Masanobu Yamada
A 39-year-old woman was admitted to our hospital with symptoms of general fatigue, nausea, and vomiting that appeared three months after she stopped seven years of medroxyprogesterone acetate (MPA) medication for endometrial stromal sarcoma. Laboratory tests demonstrated moderate hypercalcemia. Several tests demonstrated that she was suffering from adrenal insufficiency. Glucocorticoid supplementation decreased her calcium level to a normal range, indicating that hypercalcemia was induced by adrenal insufficiency...
December 8, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29201413/high-risk-sexual-behaviors-while-on-depot-medroxyprogesterone-acetate-as-compared-to-oral-contraception
#14
Deborah Bartz, Rie Maurer, Jessica Kremen, Jennifer M Fortin, Elizabeth Janiak, Alisa B Goldberg
Background: Depot medroxyprogesterone acetate (DMPA) contraceptive use is associated with an increased risk for Chlamydia infection. However, prior studies inadequately account for potential differences in sexual behavior between users of DMPA and users of other contraceptive methods. In this study we compare sexual risk-taking behavior in women using DMPA to women using oral contraceptive pills (OCP) to assess risk of Chlamydia trachomatis infection. Methods: In this cross-sectional study of 630 reproductive-aged women seeking routine gynecologic care (449 OCP and 181 DMPA users) sexual risk-taking was evaluated by use of the Safe Sex Behavior Questionnaire, a validated measure of sexual behaviors and attitudes...
2017: Contraception and Reproductive Medicine
https://www.readbyqxmd.com/read/29198157/efficacy-and-safety-evaluation-of-cimicifuga-foetida-extract-in-menopausal-women
#15
L Gao, T Zheng, W Xue, Y Wang, Y Deng, H Zuo, A Sun
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of long-term treatment with Cimicifuga foetida extract in menopausal women. METHODS: A prospective, randomized, controlled clinical trial was conducted. A total of 96 early postmenopausal women were randomly assigned to three groups: group A received 1 mg estradiol valerate daily plus 4 mg medroxyprogesterone acetate on days 19-30; group B received 1 mg estradiol valerate daily plus 100 mg micronized progesterone on days 19-30; group C received 100 mg C...
December 4, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/29197724/follicular-response-and-oocyte-production-following-variations-in-ovarian-stimulation-in-goats
#16
Claudinéia Silva Mendes, Larissa Pires Barbosa, Monna Lopes de Araújo, Emmanuel Emydio Gomes Pinheiro, Maicon Pereira Lents, Lincoln da Silva Amorim, Cláudia Kazumi Kiya, Ana Lúcia Almeida Santana
In this study, goats were subjected to ovarian stimulation protocols to evaluate possible differences in ovarian follicular responses and oocyte production. Two experiments were conducted to assess the effects of hormonal protocol duration (seven or twelve days) and number of follicle stimulating hormone (FSH) applications (one or five doses). All animals received intravaginal sponges saturated with 60 mg medroxyprogesterone acetate and an application of 125 μg cloprostenol 72 h before the sponges were removed...
November 26, 2017: Theriogenology
https://www.readbyqxmd.com/read/29188238/depot-medroxyprogesterone-acetate-administration-alters-immune-markers-for-hiv-preference-and-increases-susceptibility-of-peripheral-cd4-t-cells-to-hiv-infection
#17
Carley Tasker, Amy Davidow, Natalie E Roche, Theresa L Chang
Depot medroxyprogesterone acetate (Depo-Provera) has been associated with an increased risk of HIV acquisition. In a longitudinal study, we investigated the impact of Depo-Provera use by healthy women on expression of immune markers for HIV preference and on HIV infection ex vivo at baseline (visit 1), one month (visit 2) and three months (visit 3) after Depo-Provera treatment. We found a significant increase in the frequency and expression of integrin α4β7 on CD4+ T cells at visit 2. Interestingly, Hispanic but not black women exhibited a significant increase in integrin α4β7 cell numbers and expression levels at visit 2, whereas, black but not Hispanic women exhibited a significant change in CCR5 and CD38 expression levels between visit 2 and visit 3...
November 1, 2017: ImmunoHorizons
https://www.readbyqxmd.com/read/29172413/contraception-update-progestin-only-implants-and-injections
#18
Prium Deshmukh, Karen Antell, Elizabeth J Brown
Progestin-only contraception is a popular method of birth control in the United States and worldwide. Progestin-only implants and injections allow patients access to long-term contraception with simple options for reversal or removal. The implant is one of the most effective forms of contraception and there are few contraindications. Manufacturer-led training is required to become certified in insertion and removal. The most common adverse effect of the implant is a change in menstrual bleeding patterns. Little evidence has shown weight gain or decreased bone mineral density with use...
November 2017: FP Essentials
https://www.readbyqxmd.com/read/29172287/polycystic-ovarian-morphology-may-be-a-positive-prognostic-factor-in-patients-with-endometrial-cancer-who-achieved-complete-remission-after-fertility-sparing-therapy-with-progestin
#19
Yamato Fukui, Ayumi Taguchi, Katsuyuki Adachi, Marie Sato, Akira Kawata, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori, Kazunori Nagasaka, Yoko Matsumoto, Takahide Arimoto, Katsutoshi Oda, Yutaka Osuga, Tomoyuki Fujii
Background: The most studied fertility-sparing therapy for endometrial cancer (EC) is oral progestin therapy. However, complete remission (CR) rate after progestin therapy is not enough ranging from 60 to 80 %, with high recurrence rate. Clinical features that predict treatment efficacy and recurrence after progestin therapy have not yet been revealed in detail. The aim of this study was to investigate prognostic factors in patients with EC who achieved CR after medroxyprogesterone acetate (MPA) therapy. Methods: We retrospectively reviewed 35 EC patients treated with MPA at our institution between 2000 and 2016...
November 26, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29156102/decreasing-trends-in-number-of-depot-medroxyprogesterone-acetate-starters-in-norway-a-cross-sectional-study
#20
Ingvild Roksvaag, Finn Egil Skjeldestad
INTRODUCTION: In this study, we examined changes in depot medroxyprogesterone acetate (DMPA) prescriptions over a time-period when new professions started prescribing, and when the method gained some negative media attention. MATERIAL AND METHODS: The Norwegian Prescription Database provided data on hormonal contraception from 2006 through 2012. We estimated annual number of DMPA users by calculating doses sold per day/1000 women and calculated, for each contraceptive method on annual basis, a proportion of defined daily doses of all hormonal contraceptives in 5-year age groups at reproductive age...
November 20, 2017: Acta Obstetricia et Gynecologica Scandinavica
keyword
keyword
22363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"